Table 5.
Exploring the factors associated with autoantibodies against apolipoprotein A-I (anti-apoA-I IgG) levels.
| Anti-apoA-I IgG Levels | ||||||
|---|---|---|---|---|---|---|
| All Patients | ≤0.45 Q1 | >0.45 and ≤0.65 Q2 | >0.65 and ≤0.95 Q3 | >0.95 Q4 | P * | |
| Age, years | ||||||
| median (IQR) | 64 (54–74) | 63 (53–74) | 63 (54–74) | 64 (54–72) | 65 (55–75) | 0.1787 |
| 26–54 y | 450 (26.3%) | 122 (27.6%) | 111 (28.0%) | 109 (25.6%) | 108 (24.0%) | |
| 55–64 y | 443 (25.9%) | 121 (27.4%) | 102 (25.8%) | 114 (26.8%) | 106 (23.6%) | |
| 65–74 y | 418 (24.4%) | 99 (22.4%) | 92 (23.2%) | 110 (25.9%) | 117 (26.0%) | |
| ≥75 y | 402 (23.5%) | 100 (22.6%) | 91 (23.0%) | 92 (21.6%) | 119 (26.4%) | |
| BMI, kg/m2 | ||||||
| median (IQR) | 26.5 (24.2–29.4) | 26.2 (24.2–29.3) | 26.4 (24.2–29.3) | 26.8 (24.3–29.7) | 26.6 (24.2–29.4) | 0.6434 |
| 20–24.9 | 554 (32.8%) | 154 (35.2%) | 128 (32.4%) | 134 (32.2%) | 138 (31.3%) | |
| 25–29.9 | 767 (45.4%) | 189 (43.2%) | 187 (47.3%) | 182 (43.8%) | 209 (47.4%) | |
| 30–34.9 | 283 (16.7%) | 75 (17.1%) | 62 (15.7%) | 73 (17.5%) | 73 (16.6%) | |
| ≥35 | 86 (5.1%) | 20 (4.6%) | 18 (4.6%) | 27 (6.5%) | 21 (4.8%) | |
| missing data | 23 | 4 | 1 | 9 | 9 | |
| Female, n (%) | 363/1713 (21.2%) | 102/442 (23.1%) | 87/396 (22.0%) | 93/425 (21.9%) | 81/450 (18.0%) | 0.2669 |
| Current smoker, n (%) | 690/1680 (41.1%) | 174/436 (39.9%) | 147/390 (37.7%) | 183/419 (43.7%) | 186/435 (42.8%) | 0.2875 |
| Diabetes history, n (%) | 310/1713 (18.1%) | 97/442 (21.9%) | 66/396 (16.7%) | 83/425 (19.5%) | 64/450 (14.2%) | 0.0177 |
| Hypertension history, n (%) | 720/1713 (42.0%) | 248/442 (56.1%) | 234/396 (59.1%) | 247/425 (58.1%) | 264/450 (58.7%) | 0.8191 |
| MI history, n (%) | 246/1713 (14.4) | 53/442 (12.0%) | 52/396 (13.1%) | 73/425 (17.2%) | 68/450 (15.1%) | 0.1416 |
| Cholesterolemia history, n (%) | 1031/1711 (60.3%) | 276/441 (62.6%) | 247/395 (62.5%) | 257/425 (60.5%) | 251/450 (55.8%) | 0.1311 |
| Valvular history, n (%) | 33/1713 (1.9%) | 4/442 (0.9%) | 6/396 (1.5%) | 8/425 (1.9%) | 15/450 (3.3%) | 0.0572 |
| GRACE score | ||||||
| median (IQR) | 123 (106–142) | 123 (106–142) | 123 (106–140) | 123 (104–144) | 123 (106–143) | 0.7916 |
| ≤99 | 318 (18.6%) | 83 (18.8%) | 74 (18.7%) | 84 (19.8%) | 77 (17.1%) | |
| 100–119 | 453 (26.4%) | 121 (27.4%) | 110 (27.8%) | 100 (23.5%) | 122 (27.1%) | |
| 120–139 | 456 (26.6%) | 115 (26.0%) | 103 (26.0%) | 115 (27.1%) | 123 (27.3%) | |
| 140–159 | 303 (17.7%) | 84 (19.0%) | 65 (16.4%) | 76 (17.9%) | 78 (17.3%) | |
| ≥160 | 183 (10.7%) | 39 (8.8%) | 44 (11.1%) | 50 (11.8%) | 50 (11.1%) | |
| CRP, mg/L | ||||||
| median (IQR) | 3.0 (1.2–8.0) | 2.60 (1.10–7.70) | 2.70 (1.00–6.40) | 3.30 (1.40–8.25) | 3.10 (1.30–9.20) | 0.1704 |
| 0–0.99 | 299 (19.8%) | 77 (20.2%) | 80 (22.7%) | 63 (16.6%) | 79 (19.9%) | |
| 1–1.99 | 280 (18.5%) | 76 (19.9%) | 67 (19.0%) | 71 (18.7%) | 66 (16.6%) | |
| 2–9.99 | 614 (40.7%) | 149 (39.1%) | 141 (39.9%) | 166 (43.8%) | 158 (39.8%) | |
| ≥10 | 317 (21.0%) | 79 (20.7%) | 65 (18.4%) | 79 (20.8%) | 94 (23.7%) | |
| missing data | 203 | 61 | 43 | 46 | 53 | |
| Hs-cTnT, ng/L | ||||||
| median (IQR) | 0.22 (0.07–0.75) | 0.20 (0.06–0.67) | 0.21 (0.06–0.66) | 0.24 (0.07–0.87) | 0.26 (0.07–0.83) | 0.1947 |
| 0–0.14 | 647 (42.6%) | 172 (45.0%) | 155 (43.7%) | 158 (41.1%) | 162 (40.7%) | |
| 0.15–0.52 | 379 (25.0%) | 98 (25.7%) | 86 (24.2%) | 93 (24.2%) | 102 (25.6%) | |
| >0.52 | 493 (32.5%) | 112 (29.3%) | 114 (32.1%) | 133 (34.6%) | 134 (33.7%) | |
| missing data | 194 | 60 | 41 | 41 | 52 | |
| TMAO | ||||||
| median (IQR) | 2.93 (1.99–4.97) | 2.85 (1.89–4.97) | 2.96 (2.01–4.98) | 2.93 (2.00–4.46) | 3.05 (2.07–5.43) | 0.4744 |
| <2 | 340 (25.1%) | 98 (28.3%) | 74 (23.9%) | 83 (25.1%) | 85 (23.2%) | |
| 2–2.99 | 350 (25.9%) | 87 (25.1%) | 84 (27.2%) | 86 (26.0%) | 93 (25.3%) | |
| 3–3.99 | 206 (15.2%) | 42 (12.1%) | 51 (16.5%) | 60 (18.1%) | 53 (14.4%) | |
| 4–6.99 | 257 (19.0%) | 66 (19.1%) | 50 (16.2%) | 63 (19.0%) | 78 (21.3%) | |
| ≥7 | 200 (14.8%) | 53 (15.3%) | 50 (16.2%) | 39 (11.8%) | 58 (15.8%) | |
| missing data | 360 | 96 | 87 | 94 | 83 | |
* Kruskal-Wallis or Chi-2 tests (Fisher exact test for liver history). Abbreviations: IQR—interquartile range; BMI—body mass index; MI—myocardial infarction; GRACE—Global Registry of Acute Coronary Events; CRP—C-reactive protein; hs-cTnT—high-sensitivity troponin T; TMAO—trimethyl-amine-N-oxide.